Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.
Health-related quality of life (HR-QOL) is an important measure of health in patients with multiple sclerosis (MS), given that MS symptoms affect many aspects of everyday living. Physicians may tend to focus on physical or cognitive changes in patients with MS because these measures involve physician- or psychologist-administered tests rather than patient self-reporting. However, a number of validated instruments are available to evaluate HR-QOL in clinical studies. Several studies have used these instruments to evaluate the effects of traditional disease-modifying therapies (DMTs), i.e. interferon-beta and glatiramer acetate on HR-QOL in patients with MS. The results of many of these studies showed that DMTs improved some aspects of patients' HR-QOL, but study design issues such as small patient numbers or lack of placebo control for comparison have made it difficult to interpret these results. Two large, randomized, placebo-controlled studies of the newest DMT, natalizumab, showed that this therapy resulted in significant improvements in HR-QOL in patients with relapsing MS. Furthermore, the effects of natalizumab on HR-QOL were apparent, regardless of disease characteristics. The natalizumab studies definitively show that HR-QOL measures can be informative in a clinical trial setting and support the position that patient-reported outcomes, including HR-QOL measures, should be included in clinical trials to more fully assess therapeutic efficacy.
Rudick
Richard A
RA
Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. rudickr@ccf.org
Miller
Deborah M
DM
D006304:Health Status; D006801:Humans; D009103:Multiple Sclerosis / Q000523:psychology* / Q000628:therapy; D017063:Outcome Assessment, Health Care; D011788:Quality of Life / Q000523:psychology*; D012720:Severity of Illness Index
J Neurol Sci. 2003 Dec 15;216(1):113-8
14607312
Neurology. 1996 Jul;47(1):129-39
8710066
Med Care. 1981 Aug;19(8):787-805
7278416
Ann Neurol. 2007 Oct;62(4):335-46
17696126
Am Fam Physician. 2004 Nov 15;70(10):1935-44
15571060
Neurology. 1995 Jul;45(7):1268-76
7617181
Med Care. 1992 Jun;30(6):473-83
1593914
N Engl J Med. 2000 Sep 28;343(13):938-52
11006371
Mult Scler. 2002 Oct;8(5):377-81
12356203
Lancet. 1998 Nov 7;352(9139):1498-504
9820297
BMJ. 1997 May 31;314(7094):1580-3
9169401
Clin Rehabil. 2001 Jun;15(3):247-58
11386394
Mult Scler. 2001 Apr;7(2):137-42
11424634
Can J Neurol Sci. 1999 Nov;26(4):276-82
10563212
Mult Scler. 2006 Apr;12(2):180-6
16629421
Qual Life Res. 1995 Jun;4(3):187-206
7613530
Neurology. 1993 Apr;43(4):655-61
8469318
N Engl J Med. 2006 Mar 2;354(9):911-23
16510745
Arch Phys Med Rehabil. 1996 Apr;77(4):394-8
8607766
Can J Neurol Sci. 1998 Feb;25(1):31-8
9532278
Neurology. 1996 Apr;46(4):907-11
8780061
Lancet. 1994 Jan 29;343(8892):271-5
7905102
Qual Life Res. 1999 Sep;8(6):481-9
10548863
Mult Scler. 2003 Dec;9(6):621-6
14664477
Qual Life Res. 1993 Jun;2(3):169-80
8401453
J Neurol. 1996 Jun;243(6):469-74
8803821
Mult Scler. 1999 Oct;5(5):317-22
10516774
Neurology. 1999 Sep 22;53(5):1098-103
10496273
Brain. 1989 Feb;112 ( Pt 1):133-46
2917275
J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):710-4
12754336
Mult Scler. 2004 Dec;10(6):690-704
15584496
Epilepsy Res. 1996 Oct;25(2):113-8
8884169
N Engl J Med. 2006 Mar 2;354(9):899-910
16510744
Health Qual Life Outcomes. 2006 Dec 12;4:96
17163989
Neurology. 2002 Sep 10;59(5):679-87
12221157
Brain. 2001 May;124(Pt 5):962-73
11335698
Mult Scler. 2001 Apr;7(2):119-30
11424632
Mult Scler. 2000 Oct;6(5):338-42
11064444
Mult Scler. 2006 Dec;12(6):808-13
17263011
Neurology. 2001 Nov 27;57(10):1870-5
11723278
Ann Neurol. 1996 Mar;39(3):285-94
8602746
Int J Qual Health Care. 2000 Dec;12(6):511-7
11202605
Mult Scler. 2008 Mar;14(2):219-30
17942521
Neurology. 2001 Jul 10;57(1):68-74
11445630
Res Nurs Health. 1992 Feb;15(1):29-38
1579648
J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):144-9
10644777